Assistant Professor of Neurological Surgery and Biochemistry and Molecular Genetics
Northwestern University Feinberg School of Medicine
Dr. Saratsis has clinical appointments in the Departments of Neurological Surgery at Northwestern Memorial and Lurie Children's Hospitals, caring for children and adults with congenital disorders of the central nervous system. Dr. Saratsis has expertise in the clinical management and molecular biology of pediatric brain tumors, with particular focus on pediatric high-grade and brainstem glioma. Dr. Saratsis's laboratory aims to characterize the molecular biology of pediatric brain tumors for indentification of biomarkers of disease and development of novel, targeted therapeutic approaches to improve clinical outcomes. Dr. Saratsis is involved in multiple laboratory and clinical studies for development and clinical trial of new treatments for children with brain tumors, working closely with the neurosurgery and neuro-oncology clinical and research teams at Northwestern University and Lurie Children’s.
Ann & Robert H. Lurie Children’s Hospital of Chicago
Cracking the Histone Code: Characterizing Pediatric Brain Tumor Epigenetics using Cerebrospinal Fluid
Researchers hope to determine patterns of protein expression in glioma that could lead to advancements in the diagnostics and treatments to improve the care of pediatric patients.
Amanda Muhs Saratsis
High-grade Gliomas (HGG) or astrocytomas in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric-specific HGG preclinical models. These models are needed to help test
Low-Grade Gliomas also called astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still su
Diffuse Intrinsic Pontine Glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor. New approaches with
MSCs Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma
Through analysis of RNA sequencing data provided by CBTN, researchers bolster the use case for mesenchymal stem cells (MSCs) to deliver oncolytic virotherapy (OV) in the treatment of diffuse intrinsic pontine glioma (DIPG).
Michael Chastkofsky, Katarzyna C. Pituch, Hiroaki Katagi, Liliana Ilut, Ting Xiao, Yu Han, Adam M. Sonabend, David T. Curiel, Erin R. Bonner, Javad Nazarian, Craig Horbinski, Charles D. James, Amanda M. Saratsis, Rintaro Hashizume, Maciej S. Lesniak, Irina V. Balyasnikova